Novocure Ltd (NVCR.OQ)
NVCR.OQ on NASDAQ Stock Exchange Global Select Market
24.65USD
20 Apr 2018
24.65USD
20 Apr 2018
Change (% chg)
$-0.35 (-1.40%)
$-0.35 (-1.40%)
Prev Close
$25.00
$25.00
Open
$24.85
$24.85
Day's High
$25.50
$25.50
Day's Low
$24.55
$24.55
Volume
223,726
223,726
Avg. Vol
189,208
189,208
52-wk High
$25.65
$25.65
52-wk Low
$10.50
$10.50
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- ownership
- filings
- deals
- private equity
- third-party document and information retrieval
- estimates
- fundamentals
- economics
- events
- news
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
| Name | Age | Since | Current Position |
|---|---|---|---|
William Doyle |
54 | 2016 | Executive Chairman of the Board |
Asaf Danziger |
50 | 2012 | Chief Executive Officer, Director |
Kinyip Leung |
53 | Vice Chairman of the Board | |
Yoram Palti |
78 | 2016 | Founder, Director |
Wilhelmus Groenhuysen |
59 | 2012 | Chief Financial Officer |
- BRIEF-Novocure Says Executive Chairman William Doyle's FY 2017 Total Compensation Was $23.8 Mln
- BRIEF-Novocure Reports Positive Top-Line Results From Stellar Phase 2 Pilot Trial In Mesothelioma
- BRIEF-NCCN Guidelines Recommend Novocure's Optune In Combination With Temozolomide
- BRIEF-Novocure Ltd Reports Qtrly Net Loss Per Ordinary Share Of $0.12
- BRIEF-Novocure Secures New $150 Mln Non-Dilutive Term Loan Financing